Anti-TNFalpha therapy--killing two birds with one stone?
Arif
Sefina
S
Department of Immunobiology, King's College, Guy's Hospital, London, UK.
Cox
Patricia
P
Afzali
Behdad
B
Lombardi
Giovanna
G
Lechler
Robert I
RI
Peakman
Mark
M
Mirenda
Vincenzo
V
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab